Combined EZH2 inhibition and Ikaros degradation leads to enhanced anti-tumor activity in diffuse large B-cell lymphoma. Tong K, Yoon S, Isaev K, … Kridel R. Clinical Cancer Research, 2021.

In this paper, we identify that lenalidomide allows to sensitize resistant cell line models to the effect of tazemetostat, an EZH2 inhibitor.